IMMUPHARMA ORD 1P overview

The Life Sciences Division Initiates Coverage on ImmuPharma Plc With a BUY/Corporate Rating PR Newswire LONDON, May 28, 2019 LONDON , May 28, 2019 /PRNewswire/ -- The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announces the initiation of research on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on developing novel medicines with high sales potential in specialist markets with...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

ImmuPharma PLC: Update on Lupuzor™ Pivotal Phase III Study Full Analysis of Patient Recruitment PR Newswire LONDON, January 25, 2017 LONDON , January 25, 2017 /PRNewswire/ -- ImmuPharma PLC (LSE: IMM) , the specialist drug discovery and development company, provides further details of patient participation following confirmation in December that ImmuPharma had successfully completed, on target, patient recruitment into its pivotal Phase III clinical trial of Lupuzor™, its lead programme for...

...